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Abstract
Background: Fragile X syndrome (OMIM #300624) is the most common, recognised, heritable
cause of mental retardation. Widespread testing is warranted by the relatively high frequency of
the disorder, the benefits of early detection and the identification of related carriers whose
offspring are at a 1 in 2 risk of inheriting the expanded pathogenic mutation. However, cost-
effective screening of mentally retarded individuals has been impeded by the lack of a single, simple
laboratory test. Currently, Fragile X syndrome can be excluded in males and a majority of females
using a simple high-throughput PCR test. Due to the limited sensitivity of the PCR test, we find in
our diagnostic service that approximately 40% of females appear homozygous and a labour
intensive and expensive Southern blot test is required to distinguish these from females carrying
one normal allele and an expanded allele.
Results: We describe an improved PCR test which displays a high level of precision allowing alleles
differing by a single triplet to be resolved. Using the new assay, we detected 46/83 (53%) cryptic
heterozygotes previously labelled as homozygotes. The assay also extended the range of repeats
amplifiable, up to 170 CGG repeats in males and 130 CGG repeats in females. Combined with the
high precision, the assay also improves discrimination of normal (CGG repeats < 45) from grey
zone (45 < CGG repeats < 54) alleles and grey zone alleles from small premutations (55 < CGG
repeats < 100).
Conclusion: Use of this PCR test provides significantly improved precision and amplification of
longer alleles. The number of follow-up Southern blot tests required is reduced (up to 50%) with
consequent improvement in turnaround time and cost.
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Background
Fragile X syndrome (FXS), (OMIM #300624) is the most
common heritable cause of mental retardation, affecting
approximately 1 in 3000 males and 1 in 5000 females. As
the phenotypic presentation and frequency of clinical
signs are variable, clinical diagnosis is challenging and
definitive diagnosis in suspected individuals requires
molecular measurement of allele size. Selected screening
is highly justified among mentally retarded individuals,
not only to provide the benefits of early clinical interven-
tion but very importantly, to enable prenatal diagnosis to
be offered to related carriers whose offspring are at a 50%
risk of inheriting the expanded mutations which cause
clinical abnormality. However, no simple cost-effective
technical approach has been developed.
It is well established that FXS is caused by the large scale
expansion, beyond the normal number, of CGG repeats in
the 5'-untranslated region of the Fragile X mental retarda-
tion 1 (FMR1) gene with consequent hypermethylation of
promotor regions and shutdown of gene expression [1].
Recently, several other disorders have been attributed to
smaller scale expansions, namely Fragile X Tremor Ataxia
syndrome (FXTAS) (OMIM #300623) and Premature
Ovarian Failure (POF) (OMIM # 311360) [2]. Precise
measurement of CGG triplet expansion is therefore
increasingly important, in particular around the grey zone
and premutation repeat thresholds. Several polymerase
chain reaction (PCR) assays using a variety of primers and
enzymes have been developed for diagnostic use with var-
iable results. An assay with very high precision and the
capability of identifying larger alleles is required to detect
premutations (54 to 200 repeats) and identify
homozygous alleles in females. The latter must be further
analysed by Southern blotting to exclude the presence of
large un-amplifiable mutations. Because most PCR assays
for CGG repeats in diagnostic use have imprecision of at
least two repeats in the normal allele range, some appar-
ent homozygotes are likely to be cryptic heterozygotes
consisting of alleles differing by 1 or 2 repeats. Assays for
CGG repeats must overcome the significant problem of
amplifying long tracts of repetitive CG-rich sequence and
the associated phenomenon of enzyme stuttering which
produces heterogeneous products differing in length by 3
to 4 repeats, especially for alleles longer than 50 repeats.
To address these issues, we modified our existing PCR
method to improve its performance in terms of expanding
the range of amplifiable alleles and increasing precision.
Methods
Sample collection
We analysed DNA samples with alleles in the normal (n =
35, ≤ 45 CGG repeat) and intermediate ranges (n = 30, 45
to 54 CGG), the premutation range (n = 26, 55 to 200
CGG), and in the full mutation range (n = 15, > 200
CGG). The sizes of the tri-nucleotide repeat in all the sam-
ples had previously been determined using our old PCR
assay (CGG < 80) or by Southern Blot analysis (CGG >
80) (see below for details).
DNA was obtained from buccal and venous blood sam-
ples. Buccal cells were collected by rolling the brush firmly
on the inside of each cheek approximately 20 times.
Brushes were stored dry at 4°C and then place into a tube
containing 400 µl of 50 mM NaOH and rotated a mini-
mum of 5 times. The tubes were incubated at 95°C for 15
minutes and then 80 µl of Tris-HCl pH 7.5 added to each
tube and stored at -20°C.
DNA was obtained from venous blood samples anticoag-
ulated with EDTA. DNA was extracted using a BIO ROBOT
M48 DNA Extractor (QIAGEN).
Molecular Analysis
The old PCR was modified from a previously published
protocol using primers A  (5'-GGAACAGCGTTGAT-
CACGTGACGTGGTTTC-3') and 571R  (5'-GGGGCCT-
GCCCTAGAGCCAAGTACCTTGT-3') [3]. Amplifications
were performed in a 25 µl reaction volume containing 2.5
µl dNTPs (2 mM), 0.5 µl Pfu exo (-)enzyme (Strategene)
(2.5 U/µl), 2.5 µl Pfu buffer, 3.1 µl DMSO, 0.5 µl of
primer A (165 ng/µl) and 0.5 µl of primer 571R (165 ng/
µl) and 45–60 ng of genomic DNA. The thermocycling
program consisted of 5 minutes denaturation at 98°C,
followed by 35 cycles at 98°C for 1 minute, 62°C for 1
minute and 72°C for 2 minutes, final extension of 5 min-
u t e s  a t  7 2 ° C  i n  t h e  G e n e  A m p @  PCR System 9700
(Applied Biosystem). Results were standardised using
commercial controls of 23 and 30 repeats (Coriell Cell
Repositories) measured by sequencing.
The improved assay used primers:
c (5'-GCTCAGCTCCGTTTCGGTTTCACTTCCGGT-3') and
f  (5'AGCCCCGCACTTCCACCACCAGCTCCTCCA-
3')(Sigma) [4].
PCR amplifications were performed in a total volume of
25 µl containing 50 ng of genomic DNA or 2 µl of lysate
from buccal swabs, 0.75 pmol of each primer, 8 µl of 5×Q-
Solution (Qiagen), 2.5 µl of 10×PCR Buffer and 1 unit of
HotStarTaq Plus DNA polymerase (Qiagen) at the Gene
Amp@ PCR System 9700 (Applied Biosystem). The PCR
cycling profile was as follows: initial denaturation at 98°C
for 5 minutes; 35 cycles at 98°C for 45 seconds, 70°C for
45 seconds, and 72°C for 2 minutes, and a final extension
at 72°C for 10 minutes. PCR products were purified using
DyeEx™ 96 plates (Qiagen) before fragment analysis and
sizing by capillary electrophoresis using an automatic
sequencer (MegaBACE™ 1000 – GE HealthCareAmer-Molecular Cytogenetics 2008, 1:5 http://www.molecularcytogenetics.org/content/1/1/5
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sham). Allele sizes were determined using Genescan ROX-
550 or ROX-900 internal standard markers (Amersham
Bioscience). In a 96-well full-skirted microtitre plate, 5 µl
of purified PCR product was added to 5 µl of ROX marker
and heated to 95°C for 30 seconds. The 96-well microtitre
plate was then loaded onto the MegaBACE DNA
sequencer and run according to the manufacturer's
instructions. The collected data were analysed using Meg-
aBACE Fragment profiler version 1.2 (Amersham Bio-
science). Each run included a number of control samples
of lengths 10, 23, 29, 30, 52 and 74 repeats determined by
sequencing in-house or obtained from Coriell Cell Repos-
itories[5].
DNA sequencing was performed using the Big Dye ve3.1
Terminator cycle sequencing kit (Applied Biosystems),
and betaine (trimethylglycine) (Sigma).
Reactions were performed in a 20 µl reaction volume con-
taining of 1 µl Big Dye ve3.1 Ready Mix, 3.5 µl 5× BDT
dilution buffer, 0.5 µl of primer c or f (10 µM/µl), 10–12
ng of purified PCR product (High Pure PCR Product Puri-
fication Kit, Roche), and 4 µl of 5 M betaine dH2O at PCR
tube. The reaction was performed for 1 cycle at 98°C for 3
minutes followed by 25 cycles of 98°C for 30 seconds and
60°C for 4 minutes. The samples were precipitated by
adding 75 µl of fresh 0.2 mM MgSO4 to each tube at room
temperature and mixed thoroughly by vortexing, then
allowed to sit at room temperature for a minimum of 15
minutes. The tubes were centrifuged at 13,000 rpm in a
bench top centrifuge for 15 minutes and supernatants dis-
carded. The pellets were air-dried for 5 minutes and
sequenced.
Results
PCR Analysis
The expanded range of allele sizes in both males and
females detectable using the improved assay is shown in
Fig 1. This is at least 170 CGG repeats in males and 130
CGG repeats in females by gel visualisation. This com-
pares to an upper limit of 80 CGG repeats in male and
female samples for the previous PCR assay.
Validation of the results obtained using the improved
assay has been performed in two ways. The measurements
obtained by sequencing of 52 samples ranging from 10 to
112 repeats (the upper limit of sequencing these CG rich
regions) were compared with measurements (in triplets)
of CGG repeat length using the improved PCR assay.
There was a linear relationship, Y (sequenced repeat
number) = X (assay repeat number) + 2.4, and a correla-
tion coefficient r2 = 0.999. This correlation was used to
correct all improved assay measurement by addition of 2
triplet repeats (Y-axis intercept, 2.4 repeats). Secondly, the
This figure shows the expanded range of allele sizes (in triplet repeats) detectable with the newly designed assay using ethidium  bromide detection Figure 1
This figure shows the expanded range of allele sizes (in triplet repeats) detectable with the newly designed 
assay using ethidium bromide detection. Allele size was determined by standard curve analysis.Molecular Cytogenetics 2008, 1:5 http://www.molecularcytogenetics.org/content/1/1/5
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results obtained with the improved assay correlated very
highly with those of the old assay across the range of
amplification available with the latter (r2  = 0.997, Y
(improved assay) = 0.94× (old assay) – 0.58). Taking
these two correlations together, results obtained with the
old assay are 3 triplet repeats higher (Y-axis intercepts of
2.4 + 0.58) than those of the improved assay using the
sequenced repeat data as the standard.
There was no variation associated with different internal
sequence structures in terms of intervening AGG triplets
which numbered from none to three per allele for alleles
of 110–112 repeats.
The profiles obtained on capillary electrophoresis with
the new assay showed sharp, discrete peaks (Fig 2a and
2b). This was particularly evident with longer alleles
where comparable peaks from the old assay typically
showed broader, stuttered profiles. These sharpened
peaks provided significantly improved resolution. Re-
analysis of 83 female samples with the new assay, which
were previously reported as single allele homozygotes,
showed that 46 (53%) were actually heterozygotes with
two alleles differing by a single triplet repeat (Fig 2a and
2b). All apparent homozygous females contained alleles
in the ranges 20 to 23 repeats and 29 to 31 repeats where
the most frequent alleles are clustered [6-8].
The precision and uncertainty of measurement of the old
and new assays was compared by analysing the results of
serial repeats of control samples used in diagnostic runs.
Controls with sizes of 20, 23, 30, 52, 66, 74 and 94 CGG
repeats were used. Standard deviations and coefficients of
variation were lower across the range for the new assay
compared with the old assay (Fig 3). The general practice
of calculating 95% confidence limits for pathology meas-
urements indicates an uncertainty range of +/- 1.96 CVs
about the measured value. As a maximum CV of 1.94 was
found at 29 repeats using the old assay and 0.54 at 30
repeats for the new assay, the uncertainly of measurement
for the two assays is less than +/- 3.9% and +/- 1.1%
respectively across the range 23 to 74 CGG repeats.
Discussion
Fragile X syndrome is one of the most common genetic
disorders with a carrier frequency of approximately 1 in
800 males and 1 in 260 female in the general population
[8-10]. Its morbidity, relatively high frequency, the bene-
fits of early diagnosis and the crucial importance of iden-
tifying and offering prenatal diagnosis to carriers presents
a strong case for widespread screening of the mentally
retarded population and provision of prenatal diagnosis.
Furthermore, the recent association of premutations with
two different disorders, FXTAS and POF [8,11-13], under-
scores the importance of testing for FMR1 CGG triplet
repeat expansions. However, widespread testing has been
impeded by the lack of a single simple, cost-effective test.
Although detection of a normal result in males excludes
FMR1  premutations or full mutations, approximately
40% of females require a further time-consuming, com-
plex and expensive Southern blot test which distinguishes
homozygotes from carriers of larger alleles which PCR
testing fails to detect.
Comparison of the sensitivity between the old and the newly  designed assays Figure 3
Comparison of the sensitivity between the old and 
the newly designed assays.
Comparison of old (left) and new (right) assays in two  patients illustrating the increased sensitivity when analysing  females whose alleles differ by a single CGG triplet repeat Figure 2
Comparison of old (left) and new (right) assays in 
two patients illustrating the increased sensitivity 
when analysing females whose alleles differ by a sin-
gle CGG triplet repeat.Molecular Cytogenetics 2008, 1:5 http://www.molecularcytogenetics.org/content/1/1/5
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The aim of this study was to develop an improved PCR
assay to delineate cryptic heterozygous females and to
extend the repeat size range of alleles detected. This would
reduce the number of follow-up Southern blot tests
required, improving result turnaround times and reduce
costs of additional testing.
PCR amplification of tracts of CGG repeats greater than 70
repeats is problematic due to the high GC-rich content
which promotes formation of alternative DNA structures
[14] and the creation of polymerase pause sites which
introduces errors during replication [15]. A number of
PCR techniques have already been described which use
diverse combinations of DNA polymerase and inhibiting
secondary structure co-solvents such as dimethyl sulfox-
ide (DMSO) and betaine [8,14,16-18].
Our approach was to investigate using newer DNA
polymerases with improved fidelity and capability for
amplifying CG-rich sequences and to utilize primers that
locate closer to the CGG repeat region. HotStarTaq Plus
DNA polymerase was chosen to prevent extension of non-
specifically annealed primers and primer-dimers com-
plexes formed at low temperatures during PCR setup and
the initial PCR cycle. By changing to HotStarTaq Plus
polymerase with Q- Solution and primers c and f [4], the
upper range of amplifiable allele sizes was increased by at
least 100% and 60% for male and female samples respec-
tively (Fig 1). Typically for amplification of any repeat
sequence, the PCR products from the old assay showed
stuttered peaks when separated by capillary electrophore-
sis, especially for alleles of greater than 50 repeats. The
selection of new primers (c and f) [4] has reduced the
length of the PCR product for a 30 repeat allele from 419
base pairs for the old primers to 300 base pairs for the new
primers. This has increased the efficiency of the PCR and
theoretically maximizes the potential for separating alle-
les that differ by a single triplet repeat. Somewhat unex-
pectedly, the amplified products from the improved assay
showed significantly sharper peaks with consequent
improvement in precision of measurement. Identification
of the exact source of this improvement was attempted by
swapping primers and enzymes between the old and
improved assays protocols with no clear answer, indicat-
ing that most likely a combination of using the optimized
conditions of hot-start enzyme with its proprietary buffer
and the new primers is responsible. Alleles up to 112
repeats could be sequenced and these were used to vali-
date the assay's precision. Given this level of correlation
(r2 = 0.999) and its linearity y = x + 2.4, the improved
assay's uncertainty of measurement, defined as +/-1.96
CVs, varies from +/- < 1 triplet repeat at 20 repeats to +/- 3
CGG triplet repeats at 170 repeats, the upper limit of the
new assay's range. Using the sequenced allele data as a
standard across the range of alleles from 10 up to 112
repeats, the upper limit of sequencing this CG-rich tem-
plate, the correlation found between the old and new
assays infers that the old assay's measurements are about
1 triplet repeat higher across the range of 10–40 repeats.
Validation of FMR1  CGG triplet repeat assays used in
diagnostic laboratories is challenging due to the lack of
reliable standards. Sequenced standards are not widely
used and even here the extreme CG-rich nature of the tri-
plet repeats makes accurate sequencing difficult. The same
applies to cloning of alleles for use as standards or use of
commercially available lymphoblastoid lines. Although
errors of the order of 1–3 repeats would have no bearing
on the diagnosis of FXS they would be significant for the
detection of intermediate and small premutation alleles,
relevant to FXTAS and POF. There is an obvious need for
provision of a set of standards to be used internationally
and this is in process of being addressed [19].
The higher precision of the improved assay was used to
check the status of 83 samples which had previously given
a mono-allelic result using the old assay. All had been fur-
ther analysed by Southern blot and premutations or full
mutations were excluded in all. The assay showed that 46
(53%) were in fact biallelic with alleles differing by one
CGG triplet. As homozygous results were found in 53% of
female samples using the old assay, this finding signifi-
cantly reduces the proportion requiring follow-up South-
ern blot testing.
The other important improvement provided by use of the
new assay is to identify alleles with the potential to be
unstable when transmitted to offspring. These are grey
zone alleles (45 < CGG repeats < 54) and small premuta-
tion alleles (55 < CGG repeats < 100 CGG)[20]. Addition-
ally, precise measurement of alleles of 59 repeats or more
is important as 59 repeats is the smallest recorded allele
which has expanded to a full mutation on transmis-
sion[21].
Conclusion
The new assay offers a significant improvement in resolu-
tion and precision for measurement of alleles in the range
of 6 to 170 CGG repeats can be distinguished. Use of this
assay provides turnaround and cost advantages for diag-
nostic laboratories performing high numbers of Fragile X
syndrome tests. Importantly, the assay reduces by half the
number of follow-up Southern blot tests which are other-
wise required to exclude premutations or full mutations
in females with apparent homozygous alleles. The high
precision provided will also be of value in ongoing
research focussing on the biological interrelationships
and clinical significance of normal, gray zone and small
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